11:32:12 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-20 Kvartalsrapport 2024-Q3
2024-08-28 Kvartalsrapport 2024-Q2
2024-05-28 Kvartalsrapport 2024-Q1
2024-05-15 X-dag ordinarie utdelning ISAB 0.00 SEK
2024-05-14 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-11-22 Kvartalsrapport 2023-Q3
2023-08-29 Kvartalsrapport 2023-Q2
2023-05-31 Kvartalsrapport 2023-Q1
2023-05-15 X-dag ordinarie utdelning ISAB 0.00 SEK
2023-05-12 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-22 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-06-08 X-dag ordinarie utdelning ISAB 0.00 SEK
2022-05-23 Kvartalsrapport 2022-Q1
2022-05-06 Årsstämma 2022
2022-02-28 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-06-22 Extra Bolagsstämma 2021
2021-06-09 X-dag ordinarie utdelning ISAB 0.00 SEK
2021-06-08 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-06-12 Extra Bolagsstämma 2020
2020-05-13 X-dag ordinarie utdelning ISAB 0.00 SEK
2020-05-12 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-22 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-05-10 X-dag ordinarie utdelning ISAB 0.00 SEK
2019-02-21 Bokslutskommuniké 2018
2018-12-13 Extra Bolagsstämma 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-24 X-dag ordinarie utdelning ISAB 0.00 SEK
2018-05-23 Årsstämma 2018
2018-05-16 Kvartalsrapport 2018-Q1
2018-02-22 Bokslutskommuniké 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-28 Kvartalsrapport 2017-Q2

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Inhalation Sciences Sweden, ISAB, är ett forskningsbolag. Idag innehas störst fokus mot framställning och utvecklande av laboratorieinstrument. Instrumenten används för att mäta partiklar i inandningsluften och hur luftens sammansättning påverkar lungorna. Bolaget säljer produkter under varierade varumärken, främst på den europeiska marknaden. Inhalation Sciences Sweden grundades 2004 och har sitt huvudkontor i Huddinge.
2020-10-15 08:00:00

(Stockholm, 15 October 2020) The Journal of Aerosol Science has published a new paper on In Vitro-In Vivo Correlation (IVIVC) that demonstrates how data generated from ISAB's in vitro simulation tool DissolvIt [®] [ ]successfully emulated data from its in vivo IPL (Isolated Perfuse Lung) tool. The paper was authored by Per Gerde, CSO at ISAB, Assoc Prof Karolinska Institutet, Institute of Environmental Medicine (IMM), Maria Malmlöf, ISAB's Director of Projects and Dr Ewa Selg, ISAB's Ex Vivo In Vivo specialist.

A new paper is published in the Journal of Aerosol Science demonstrates how Inhalation Sciences' in vitro simulation tool DissolvIt[®][ ]produced data that emulated and correlated with data produced from the company's ex vivo IPL tool IPL (Isolated Perfused Lung of the rat). The two aerosols tested were nicotine and fluticasone propionate. Using the two highly sophisticated methods enabled exceptionally close comparison. The paper explores and reflects in detail on the comparative reasons for and results from both modules - when they matched closely and when they diverged.

In Vitro In Vivo Correlation (IVIVC) of data has been long sought-after amongst inhalation scientists. Being able to reliably correlate in vitro dissolution data with in vivo data enables inhaled drug developers to identify promising Drug Candidates or New Formulations and eliminate weak ones from the beginning - optimizing research planning and protocols and delivering a strategic headstart. For environmental toxicologists IVIVC offers important benefits, improving risk assessments of air pollutants.

ISAB CSO. Per Gerde: "This is an important paper both for us and inhalation research as a whole. It shows that achieving in vitro to in vivo correlation for inhaled aerosols is no doubt a challenge, but by having tuned the DissolvIt[® ]closer to the properties of a real lung we can much closer emulate clinical data." The publication is titled "In Vitro to Ex Vivo/In Vivo Correlation (IVIVC) of Dissolution Kinetics from Inhaled Particulate Solutes Using Air/Blood Barrier Models: Relation Between In Vitro Design, Lung Physiology and Kinetic Output of Models". It is co-authored by Inhalation Sciences and IMM, Karolinska Institutet.

Read the publication HERE. (https://www.sciencedirect.com/science/article/pii/S002185022030183X?dgcid=author)